Quoin reports QRX003 clears skin in pediatric Netherton syndrome case study

Bitget2026/10/20 10:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Quoin Pharmaceuticals announced publication of a peer-reviewed QRX003 pediatric Netherton syndrome case report in Dermatology and Therapy, published October 13, 2026.
The patient's severe skin symptoms largely cleared during 21 months of compassionate-use treatment; itching resolved.
No treatment-related adverse events were reported; the single-patient findings require further evaluation in clinical trials.
Positive interim Phase 2/3 results reported in August showed skin improvement in most evaluated participants.
Recruitment of all 20 participants is expected by year-end 2026, with topline results due in the second quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200630PRIMZONEFULLFEED9848810) on October 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Quoin reports QRX003 clears skin in pediatric Netherton syndrome case study

You may also like

Crypto prices